EP2094693A2 - A method for the preparation of solifenacin - Google Patents

A method for the preparation of solifenacin

Info

Publication number
EP2094693A2
EP2094693A2 EP07855994A EP07855994A EP2094693A2 EP 2094693 A2 EP2094693 A2 EP 2094693A2 EP 07855994 A EP07855994 A EP 07855994A EP 07855994 A EP07855994 A EP 07855994A EP 2094693 A2 EP2094693 A2 EP 2094693A2
Authority
EP
European Patent Office
Prior art keywords
solifenacin
accordance
phenyl
base
hydrogen tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07855994A
Other languages
German (de)
French (fr)
Other versions
EP2094693B1 (en
Inventor
Josef Jirman
Richard Junek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Priority to PL07855994T priority Critical patent/PL2094693T3/en
Publication of EP2094693A2 publication Critical patent/EP2094693A2/en
Application granted granted Critical
Publication of EP2094693B1 publication Critical patent/EP2094693B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Definitions

  • the invention deals with a new method of preparation of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3- yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate of formula III (solifenacin), which is used for symptomatic treatment of urgent incontinence and/or increased frequency of urinating and urgency of urinating in patients with hyperactive urinary bladder.
  • the first method consists in the reaction of (lS)-ethyl l-phenyl-l,2,3,4-tetrahydro-2- isoquinoline carboxylate of formula II with 3-(R)-quinuclidol of formula I in a toluene suspension and in the presence of sodium hydride.
  • the reaction mixture is refluxed with simultaneous distillation of the ethanol being formed, which leaves in the form of an azeotropic mixture with toluene.
  • Another method of production described in the patent is the reaction of l-phenyl-1,2,3,4- tetrahydro-2-isoquinoline carbonyl chloride of formula IV with 3-quinuclidol of formula V in dimethylformamide, producing l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate of formula VI.
  • the invention provides a new method of preparation of optically pure (1S)-(3R)-1- azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate (solifenacin) or its pharmaceutically acceptable salts, which consists in the preparation of solifenacin hydrogen tartrate in a crystalline form.
  • the invention is based on the exceptionally good purification effect of the transformation of the crude base to the hydrogen tartrate by the action of L-tartaric acid and subsequent isolation of crystalline solifenacin hydrogen tartrate.
  • the method of the invention can be used for purification of solifenacin prepared by any known method of preparation, in particular for solifenacin prepared by reaction of (lS)-alkyl 1- phenyl-l,2,3,4-tetrahydro-2-isoquinoline carboxylate with s 3-(R)-quinuclidol with catalysis of a non-nucleophilic base.
  • Solifenacin hydrogen tartrate has not been prepared and characterized so far.
  • Crystalline solifenacin hydrogen tartrate is a stable salt that can be transformed to another pharmaceutically acceptable solifenacin salt, e.g. succinate, or used directly for the preparation of a medicament.
  • This salt has been characterized by the X-ray, DSC, ER. and CP-MAS 13 C NMR spectroscopy methods.
  • the method of the invention can be carried out, e.g., in the following manner:
  • a reaction mixture with crude solifenacin, prepared by any known method (see above) is cooled after the achievement of the conversion and water is added to the mixture. After separation of the organic phase the aqueous layer is washed with another portion of the organic solvent. The combined organic extracts are washed with water, saline and finally with water again. The organic layer is subsequently evaporated to dryness.
  • solifenacin As purification of solifenacin by its crystallization in the form of the HCl salt or oxalate has manifested low efficiency, there was an effort to find a more suitable way of purification of crude solifenacin.
  • the process that has proved to represent the most efficient way of preparation of solifenacin is the process comprising: the preparation of the solifenacin base by reaction of (lS)-alkyl 1- phenyl-l,2,3,4-tetrahydro-2-isoquinoline carboxylate with 3-(R)-quinuclidol with catalysis by a non-nucleophilic base (Scheme 1),
  • Scheme 1 further the isolation of the crude base and subsequent final purification, which consists in transforming the solifenacin base to the hydrogen tartrate by the action of L-tartaric acid in the environment of a polar solvent or mixture of polar solvents, and isolation of crystalline solifenacin hydrogen tartrate.
  • the solifenacin hydrogen tartrate pure salt prepared this way can be transformed to pharmaceutically commonly used solifenacin succinate, or directly used for the preparation of a medicament.
  • a non-nucleophilic base is a base having considerably reduced capability of nucleophilic substitution.
  • This is mainly the case of sterically hindered alcoholates or amines, further of lithium compounds or of the group of substances called phosphazenes, in particular e.g. potassium tert-butoxide, sodium tert-butoxide, tert-butyllithium, LDA, K-HMDS, DBU, DBN, 2,6-di-tert-butyl-4-methylpyridine, Pl-t-Bu base, BEMP, BTPP and P2-t-Bu base while potassium tert-butoxide and sodium or potassium tert-amylate are especially suitable.
  • From the group of polar solvents for the preparation and isolation of hydrogen tartrate it is most suitable to use C 1 -C 4 alcohols, their mixtures and possibly their combinations with water.
  • Solifenacin tartrate can be alternatively prepared in such a way that L-tartaric acid is added directly to the organic phase with the crude solifenacin base, i.e. without prior isolation of the base, e.g. in such a way that an equivalent of the saturated solution of L-tartaric acid in an alcohol is added to the solution of the crude base in a non-polar solvent. Solifenacin hydrogen tartrate is precipitated, sucked off and subsequently crystallized in a usual way.
  • Figure 1 represents an XRPD diffraction pattern of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
  • Figure 2 represents an IR spectrum of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
  • Figure 3 represents a CP-MAS 13 C NMR spectrum of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- ⁇ henyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
  • Figure 4 represents a DSC curve of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate
  • 3(i?)-Quinuclidol (0.1 - 0.15 mmol) is added to a solution of l(_S)-ethyl l-phenyl-1,2,3,4- tetrahydro-2-isoquinoline carboxylate (0.1 mmol) in toluene (25 ml).
  • potassium tert-butanolate (0 - 0.05 mmol) is added to the mixture during continuous stirring and the resulting fine suspension is heated up to boil.
  • the azeotropic mixture toluene - alcohol is gradually removed from the mixture by distillation. The reaction is completed after the achievement of the corresponding conversion.
  • the optical purity of the product was determined with capillary electrophoresis.
  • solifenacin hydrochloride An equivalent of a 3M solution of hydrogen chloride in methanol was added to the solution and the mixture was left to freely crystallize at the room temperature. After sucking off and washing, 42% of solifenacin hydrochloride was obtained, which contained 1.7 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l- ⁇ henyl-2(lH)- isoquinoline carboxylate hydrochloride, 0.6 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrochloride and 1.3 % of l(S)-phenyl- 1,2,3,4-tetrahydroisoquinoline hydrochloride, hi crystallizing the product from methylethylketone 58 % of solifenacin hydro
  • solifenacin hydrochloride After the second crystallization from methylethylketone 63 % of solifenacin hydrochloride was obtained, which contained 0.4 % of (1R)-(3R)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro- 1 -phenyl-2(lH)-isoquinoline carboxylate hydrochloride, 0.18 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate hydrochloride and 0.3% of l(S)-phenyl-l,2,3,4- tetrahydroisoquinoline hydrochloride.
  • the organic extracts were washed with 100 ml of water, 50 ml of saline, 50 ml of water and evaporated in a rotational vacuum evaporator 12.7 g of the solifenacin base was obtained that contained the following impurities (CE analysis).
  • solifenacin base prepared in accordance with procedure 8 was dissolved in 50 ml of a methanol:2-propanol (1:1) mixture, an equivalent of L-tartaric acid in a methanol:2- propanol (1:1) mixture was added and the mixture was left to freely crystallize at the room temperature. After sucking off and washing, 79 % of solifenacin hydrogen tartrate was .
  • solifenacin hydrogen tartrate In crystallizing the product from the methanol:2-propanol (3:4) mixture 94 % of solifenacin hydrogen tartrate was obtained, which contained 0.6% of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-fenyl-2(lH)- isoquinoline carboxylate hydrogen tartrate and 0.4 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
  • solifenacin succinate After sucking off and washing, 66% of solifenacin succinate was obtained, which contained 1.0% of (1R)-(3R)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate, 0.7 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate and 0.3 % of l(S)-phenyl- 1,2,3,4-tetrahydroisoquinoline.
  • solifenacin succinate After the second crystallization from 2-propanol 89% of solifenacin succinate was obtained, which contained 0.17 % (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate, 0.33 % of (1S)-(3S)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate and 0.07 % of l(S)-phenyl-l,2 3 3,4-tetrahydroisoquinoline.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

A method of preparing (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate (solifenacin) or its pharmaceutically acceptable salts with high optic purity, wherein the crude solifenacin base is transformed to the hydrogen tartrate, which is then optionally transformed to another pharmaceutically acceptable salt or the base of solifenacin. A crystalline salt of solifenacin hydrogen tartrate.

Description

A METHOD FOR THE PREPARATION OF SOLIFENACIN
TECHNICAL FIELD
The invention deals with a new method of preparation of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3- yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate of formula III (solifenacin), which is used for symptomatic treatment of urgent incontinence and/or increased frequency of urinating and urgency of urinating in patients with hyperactive urinary bladder.
BACKGROUND ART
The original patent literature (EP 0 801 067, WO 9620194) describes several methods of preparation of solifenacin.
The first method consists in the reaction of (lS)-ethyl l-phenyl-l,2,3,4-tetrahydro-2- isoquinoline carboxylate of formula II with 3-(R)-quinuclidol of formula I in a toluene suspension and in the presence of sodium hydride. The reaction mixture is refluxed with simultaneous distillation of the ethanol being formed, which leaves in the form of an azeotropic mixture with toluene.
Formula I Formula II Formula III
Another method of production described in the patent is the reaction of l-phenyl-1,2,3,4- tetrahydro-2-isoquinoline carbonyl chloride of formula IV with 3-quinuclidol of formula V in dimethylformamide, producing l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate of formula VI.
Formula FV Formula V Formula VI In EP 0 801 067, or WO 9620194 another version is published, where 3-(R)-quinuclidyl alkyl carbonate is reacted with 1 -phenyl- 1, 2,3, 4-tetrahydro-2-isoquinoline to produce solifenacin. Crude solifenacin obtained with the use of one of the above mentioned methods of preparation is subsequently isolated as the hydrochloride or oxalate and during their crystallization purification from unreacted starting materials and side products occurs. However, the purifying effect of the transformation to these salts is small. To achieve purity that is suitable for the preparation of the end product, solifenacin succinate, which is used for the preparation of medicaments, the crystallization of HCl or oxalate must be repeated several times, which naturally reduces the yields.
DISCLOSURE OF INVENTION
The invention provides a new method of preparation of optically pure (1S)-(3R)-1- azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate (solifenacin) or its pharmaceutically acceptable salts, which consists in the preparation of solifenacin hydrogen tartrate in a crystalline form. The invention is based on the exceptionally good purification effect of the transformation of the crude base to the hydrogen tartrate by the action of L-tartaric acid and subsequent isolation of crystalline solifenacin hydrogen tartrate.
The method of the invention can be used for purification of solifenacin prepared by any known method of preparation, in particular for solifenacin prepared by reaction of (lS)-alkyl 1- phenyl-l,2,3,4-tetrahydro-2-isoquinoline carboxylate with s 3-(R)-quinuclidol with catalysis of a non-nucleophilic base.
Solifenacin hydrogen tartrate has not been prepared and characterized so far. Crystalline solifenacin hydrogen tartrate is a stable salt that can be transformed to another pharmaceutically acceptable solifenacin salt, e.g. succinate, or used directly for the preparation of a medicament.
This salt has been characterized by the X-ray, DSC, ER. and CP-MAS 13C NMR spectroscopy methods.
The method of the invention can be carried out, e.g., in the following manner:
A reaction mixture with crude solifenacin, prepared by any known method (see above) is cooled after the achievement of the conversion and water is added to the mixture. After separation of the organic phase the aqueous layer is washed with another portion of the organic solvent. The combined organic extracts are washed with water, saline and finally with water again. The organic layer is subsequently evaporated to dryness.
After this purification some impurities still remain in the reaction mixture, such as (1R)-(3R)- l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-ρhenyl-2(lH)-isoquinoline carboxylate, (IS)-(SS)- l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate and 1(S)- phenyl-l,2,3,4-tetrahydroisoquinoline.
As purification of solifenacin by its crystallization in the form of the HCl salt or oxalate has manifested low efficiency, there was an effort to find a more suitable way of purification of crude solifenacin.
What has proved to be more suitable was to convert the solifenacin base to the succinate by the action of succinic acid. However, by far the best cleaning effect was achieved with the conversion of the crude solifenacin base to the hydrogen tartrate crystalline salt by the action of L-tartaric acid. The crystalline form of the hydrogen tartrate of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate has been characterized by means of the X- ray diffraction pattern method (signals at 3.9 , 11.6 , 12.1 , 13.9 , 17.8 , 19.5 and 24.5 ± 0.2 degrees 2Θ), IR and CP-MAS 13C NMR spectroscopies and DSC (1 peak at 200.0 °C) (Figures 1 to 4).
The process that has proved to represent the most efficient way of preparation of solifenacin is the process comprising: the preparation of the solifenacin base by reaction of (lS)-alkyl 1- phenyl-l,2,3,4-tetrahydro-2-isoquinoline carboxylate with 3-(R)-quinuclidol with catalysis by a non-nucleophilic base (Scheme 1),
R - primary alkyl (C) - C4)
Scheme 1 further the isolation of the crude base and subsequent final purification, which consists in transforming the solifenacin base to the hydrogen tartrate by the action of L-tartaric acid in the environment of a polar solvent or mixture of polar solvents, and isolation of crystalline solifenacin hydrogen tartrate. The solifenacin hydrogen tartrate pure salt prepared this way can be transformed to pharmaceutically commonly used solifenacin succinate, or directly used for the preparation of a medicament.
A non-nucleophilic base is a base having considerably reduced capability of nucleophilic substitution. This is mainly the case of sterically hindered alcoholates or amines, further of lithium compounds or of the group of substances called phosphazenes, in particular e.g. potassium tert-butoxide, sodium tert-butoxide, tert-butyllithium, LDA, K-HMDS, DBU, DBN, 2,6-di-tert-butyl-4-methylpyridine, Pl-t-Bu base, BEMP, BTPP and P2-t-Bu base while potassium tert-butoxide and sodium or potassium tert-amylate are especially suitable. From the group of polar solvents for the preparation and isolation of hydrogen tartrate it is most suitable to use C1-C4 alcohols, their mixtures and possibly their combinations with water.
Solifenacin tartrate can be alternatively prepared in such a way that L-tartaric acid is added directly to the organic phase with the crude solifenacin base, i.e. without prior isolation of the base, e.g. in such a way that an equivalent of the saturated solution of L-tartaric acid in an alcohol is added to the solution of the crude base in a non-polar solvent. Solifenacin hydrogen tartrate is precipitated, sucked off and subsequently crystallized in a usual way.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 represents an XRPD diffraction pattern of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
Figure 2 represents an IR spectrum of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate.
Figure 3 represents a CP-MAS 13C NMR spectrum of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-ρhenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate. Figure 4 represents a DSC curve of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate
EXAMPLES General procedure of examples 1-6
3(i?)-Quinuclidol (0.1 - 0.15 mmol) is added to a solution of l(_S)-ethyl l-phenyl-1,2,3,4- tetrahydro-2-isoquinoline carboxylate (0.1 mmol) in toluene (25 ml). After heating to 90 °C and complete dissolution of both starting substances potassium tert-butanolate (0 - 0.05 mmol) is added to the mixture during continuous stirring and the resulting fine suspension is heated up to boil. The azeotropic mixture toluene - alcohol is gradually removed from the mixture by distillation. The reaction is completed after the achievement of the corresponding conversion.
The course of the reaction (substance conversion) was monitored with gas chromatography.
The optical purity of the product was determined with capillary electrophoresis.
The results of analyses of the products prepared in accordance with examples 1 - 6 are summarized in the table.
Example 7:
4 g of the solifenacin base prepared in accordance with procedure 6, which contained 4.5 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxyiate!, 1.4 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate and 4.0 % of l(S)-phenyl-l,2,3,4-tetrahydroisoquinoline were dissolved in 30 ml of methylethylketone. An equivalent of a 3M solution of hydrogen chloride in methanol was added to the solution and the mixture was left to freely crystallize at the room temperature. After sucking off and washing, 42% of solifenacin hydrochloride was obtained, which contained 1.7 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-ρhenyl-2(lH)- isoquinoline carboxylate hydrochloride, 0.6 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrochloride and 1.3 % of l(S)-phenyl- 1,2,3,4-tetrahydroisoquinoline hydrochloride, hi crystallizing the product from methylethylketone 58 % of solifenacin hydrochloride was obtained, which contained 0.9 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrochloride, 0.4 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-ρhenyl-2(lH)- isoquinoline carboxylate hydrochloride and 0.7% of l(S)-phenyl-l,2,3,4- tetrahydroisoquinoline hydrochloride. After the second crystallization from methylethylketone 63 % of solifenacin hydrochloride was obtained, which contained 0.4 % of (1R)-(3R)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro- 1 -phenyl-2(lH)-isoquinoline carboxylate hydrochloride, 0.18 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate hydrochloride and 0.3% of l(S)-phenyl-l,2,3,4- tetrahydroisoquinoline hydrochloride.
Example 8:
3(i?)-Quinuclidol (44.3 mmol) was added to a solution of l(5)-ethyl 1 -phenyl- 1,2,3 ,4- tetrahydro-2-isoquinoline carboxylate (36.7 mmol) in 250 ml of toluene. After heating to 90 °C and complete dissolution of both starting substances potassium tert-smylate (7.4 mmol) was added to the mixture during continuous stirring and the resulting fine suspension was heated up to boil. The azeotropic mixture toluene - alcohol was gradually removed from the mixture by distillation. The reaction was finished after 3 hours of boiling, when the conversion in accordance with GC achieved 96%. Water (100 ml) was added to the mixture and the mixture was stirred at the laboratory temperature for 30 minutes. After the separation of the toluene layer in a separator the aqueous layer was washed with toluene (2x 100 ml). The combined organic extracts were then further extracted with 150 ml of diluted hydrochloric acid (6.1 mmol) and the toluene layer was then washed with water (2x 50ml). Then, the aqueous extracts were alcalinized with potassium carbonate (10.9 mmol) and extracted wjrth toluene (3x 100ml). The organic extracts were washed with 100 ml of water, 50 ml of saline, 50 ml of water and evaporated in a rotational vacuum evaporator 12.7 g of the solifenacin base was obtained that contained the following impurities (CE analysis). 3.2 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate, 1.1 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate and 6.0 % of l(S)-phenyl-l,2,3,4-tetrahydroisoquinoline.
Example 9:
One half of the solifenacin base prepared in accordance with procedure 8 was dissolved in 50 ml of a methanol:2-propanol (1:1) mixture, an equivalent of L-tartaric acid in a methanol:2- propanol (1:1) mixture was added and the mixture was left to freely crystallize at the room temperature. After sucking off and washing, 79 % of solifenacin hydrogen tartrate was . obtained, which contained 1.1 % of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l- fenyl-2(lH)-isoqumoline carboxylate hydrogen tartrate, 0.6 % of (1S)-(3S)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate and no l(S)-phenyl -1,2,3,4-tetrahydroisoquinoline. In crystallizing the product from the methanol:2-propanol (3:4) mixture 94 % of solifenacin hydrogen tartrate was obtained, which contained 0.6% of (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-fenyl-2(lH)- isoquinoline carboxylate hydrogen tartrate and 0.4 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate hydrogen tartrate. After the second crystallization from ethanol 89% of solifenacin hydrogen tartrate was obtained, which did not contain any detectable impurities. The product was characterized by means of the following analytical methods: X-ray, IR and CP-MAS 13C NMR spectroscopies and DSC.
Example 10:
The other half of the solifenacin base prepared in accordance with procedure 8 was dissolved in 15 ml of 2-propanol, an equivalent of succinic acid in 55 ml of 2-proρanol was added and the mixture was left to freely crystallize at the room temperature. After sucking off and washing, 66% of solifenacin succinate was obtained, which contained 1.0% of (1R)-(3R)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate, 0.7 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate and 0.3 % of l(S)-phenyl- 1,2,3,4-tetrahydroisoquinoline. In crystallizing the product from 2-propanol 86% of solifenacin succinate was obtained, which contained 0.41% of(lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-ρhenyl-2(lH)-isoquinoline carboxylate succinate, 0.35 % of (lS)-(3S)-l-azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl- 2(lH)-isoquinoline carboxylate succinate and 0.1 % of l(S)-phenyl-l,2,3,4- tetrahydroisoquinoline. After the second crystallization from 2-propanol 89% of solifenacin succinate was obtained, which contained 0.17 % (lR)-(3R)-l-azabicyclo[2.2.2.]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate, 0.33 % of (1S)-(3S)-1- azabicyclo[2.2.2.]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-isoquinoline carboxylate succinate and 0.07 % of l(S)-phenyl-l,233,4-tetrahydroisoquinoline.

Claims

1. A method for the preparation of (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l- phenyl-2(lH)-isoquinoline carboxylate (solifenacin) or its pharmaceutically acceptable salts with high optic purity, characterized in that the crude solifenacin base is converted to the hydrogen tartrate, which is then optionally converted to another pharmaceutically acceptable salt or the base of solifenacin.
2. The method in accordance with claim 1, characterized by in that the solifenacin base is converted to the hydrogen tartrate by the action of L-tartaric acid and crystalline solifenacin hydrogen tartrate is subsequently isolated.
3. The method in accordance with claim 2, characterized in that solifenacin hydrogen tartrate is further re-crystallized from a polar solvent or a mixture of polar solvents, preferably from the group OfC1-C4 alcohols, or their combination with water.
4. The method in accordance with claims 2 and 3, characterized in that the crude solifenacin base is prepared by reaction of (lS)-alkyl 1 -phenyl- 1,2,3 ,4-tetrahydro-2- isoquinoline carboxylate, where alkyl means a primary C1-C4 alkyl, with 3-(R)- quinuclidol in the environment of a non-nucleophilic base.
5. The method in accordance with claim 4, characterized in fact that a non-nucleophilic base from the group of sterically hindered alcoholates or amines, or lithium compounds, or phosphazenes, is used.
6. The method in accordance with claim 5, characterized in that potassium, sodium or lithium tert-butanolate is used.
7. The method in accordance with claim 5, characterized in that potassium or sodium tert- amylate is used.
8. A crystalline salt of solifenacin hydrogen tartrate.
9. The crystalline salt in accordance with claim 8, characterized by the X-ray spectrum record with typical signals at: 3.9, 11.6, 12.1, 13.9, 17.8, 19.5 and 24,5 ± 0,2 degrees 2Θ.
10. The crystalline salt in accordance with claim 8, characterized by the DSC record with 1 endotherm with the peak at 200.0 °C at the heating speed of 10 °C/min.
11. The crystalline salt in accordance with claim 8, characterized by the signals at 11.2
19.6 24.7 27.1 38.1 45.8 47.4 52.9 56.4 70.1 73.7 75.3 125.7 127.9 128.8 133.7 137.2 145.2 154.6 177.0 ppm in the CP/13 C MAS NMR spectrum.
EP07855994A 2006-12-22 2007-12-21 A method for the preparation of solifenacin Not-in-force EP2094693B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL07855994T PL2094693T3 (en) 2006-12-22 2007-12-21 A method for the preparation of solifenacin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20060828A CZ300692B6 (en) 2006-12-22 2006-12-22 Method for preparing solifenacin
PCT/CZ2007/000119 WO2008077357A2 (en) 2006-12-22 2007-12-21 A method for the preparation of solifenacin

Publications (2)

Publication Number Publication Date
EP2094693A2 true EP2094693A2 (en) 2009-09-02
EP2094693B1 EP2094693B1 (en) 2011-11-16

Family

ID=39327062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07855994A Not-in-force EP2094693B1 (en) 2006-12-22 2007-12-21 A method for the preparation of solifenacin

Country Status (9)

Country Link
US (1) US20100145055A1 (en)
EP (1) EP2094693B1 (en)
AT (1) ATE533764T1 (en)
CZ (1) CZ300692B6 (en)
EA (1) EA015365B1 (en)
ES (1) ES2375668T3 (en)
PL (1) PL2094693T3 (en)
UA (1) UA96974C2 (en)
WO (1) WO2008077357A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229387A1 (en) 2007-12-04 2010-09-22 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts
PL3067353T3 (en) 2008-07-29 2018-04-30 Krka, D.D., Novo Mesto A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
CA2804107A1 (en) 2010-07-05 2012-01-12 Crystal Pharma S.A.U. Solifenacin salts
CN102887894A (en) * 2011-07-18 2013-01-23 天津市医药集团技术发展有限公司 Crystal form of solifenacin succinate and preparation method thereof
KR101427221B1 (en) * 2012-08-29 2014-08-13 주식회사 에스텍파마 Proces for purifying fluvoxamine free base and process for preparing high purity fluvoxamine maleate using the same
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52108992A (en) * 1976-03-10 1977-09-12 Meiji Seika Kaisha Ltd Purification of cefalexin
NO2005012I1 (en) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin and pharmaceutically acceptable salts thereof
US20080287680A1 (en) * 2004-02-09 2008-11-20 Astellas Pharma Inc. Solifenacin Succinate-Containing Composition
WO2005087231A1 (en) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Solifenacin-containing composition
JP3701964B1 (en) * 2005-03-08 2005-10-05 アステラス製薬株式会社 Novel salts of quinuclidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008077357A2 *

Also Published As

Publication number Publication date
UA96974C2 (en) 2011-12-26
CZ2006828A3 (en) 2008-07-02
EA200900744A1 (en) 2009-12-30
EP2094693B1 (en) 2011-11-16
CZ300692B6 (en) 2009-07-15
ES2375668T3 (en) 2012-03-05
WO2008077357A3 (en) 2008-08-14
WO2008077357A2 (en) 2008-07-03
ATE533764T1 (en) 2011-12-15
EA015365B1 (en) 2011-06-30
PL2094693T3 (en) 2012-04-30
US20100145055A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
US20140228575A1 (en) Process for the Preparation of Solifenacin and Salts Thereof
CN102503840B (en) Preparation method of dezocine
EP2094693A2 (en) A method for the preparation of solifenacin
US8034942B2 (en) Process for the preparation of solifenacin
WO1996001824A1 (en) Process for the preparation of 2-(1-azabicyclo(2.2.2)oct-3-yl) -2,4,5,6-tetrahydro-1h-benz(de)isoquinolin-1-one and intermediate product
WO2008019055A2 (en) Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
AU2008331168A1 (en) Crystalline form I of lamivudine and its preparation
WO2009122429A2 (en) Crystalline oxybutynin and process for preparing the same
KR20110010803A (en) Process for preparing enantiomerically pure (S) -1-phenyl-1,2,3,4-tetrahydroisoquinoline
WO2014005601A1 (en) A process for the preparation of solifenacin or a salt thereof
JP2007515459A (en) How to get tolterodine
EP2540717B1 (en) Lamivudine oxalate and preparation method thereof
AU2010277144A1 (en) Polymorphic form of toremifene citrate and process for its preparation
CN111777554A (en) Method for synthesizing cisatracurium besilate
JP4258104B2 (en) trans-dicyclohexyl-3,3'4,4'-tetracarboxylic acid tetramethyl and tetraethyl
US20120267533A1 (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride
CN121358709A (en) Method for preparing 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}phenyl-1,3-diol hemifumarate
HK1180338A (en) Lamivudine oxalate and preparation method thereof
WO2006018703A2 (en) Processes for preparation of narwedine and its use in the synthesis of galantamine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090623

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20091112

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KATZAROV S.A.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007018825

Country of ref document: DE

Effective date: 20120119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20111219

Year of fee payment: 5

Ref country code: ES

Payment date: 20111128

Year of fee payment: 5

Ref country code: CH

Payment date: 20111129

Year of fee payment: 5

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20111116

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2375668

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120305

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120316

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 11111

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120316

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120217

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20111222

Year of fee payment: 5

Ref country code: RO

Payment date: 20120215

Year of fee payment: 5

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E013415

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120216

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 533764

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111116

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20120817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111221

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007018825

Country of ref document: DE

Effective date: 20120817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111116

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20121221

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 11111

Country of ref document: SK

Effective date: 20121221

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130830

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007018825

Country of ref document: DE

Effective date: 20130702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130702

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121221

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121221

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121221

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121222

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20141120

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20141205

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151221